The Genomics Core provides consultation and state-of-the-art genomic technologies to KCI investigators. Core scientists interact with KCI researchers to design experiments, generate preliminary data, write methodologies, and generate and analyze experimental data. The Core supports research investigating genetic factors: a) responsible for cancer susceptibility, b) involved in neoplastic initiation and progression, and c) affecting cancer treatment. Existing Core technologies include: 1) nucleic acid isolation (Qiagen TissueLyser, AutoPure and EZ1 Advanced); 2) DNA sequencing (Applied Biosystems 3730 and 3100); 3) genotyping (Applied Biosystems 7900, lllumina iScan, and Affymetrix GeneChip System); 4) expression analysis (Applied Biosystems 7900, lllumina iScan, and Affymetrix GeneChip System);and 5) Next Generation Sequencing (lllumina Genome Analyzer NX with paired-end module).
The Genomics Core supports research investigating genetic factors responsible for cancer susceptibility involved in neoplastic initiation and progression, and affecting cancer treatment using high-throughput technologies in a cost-effective manner.
|Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562|
|Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294|
|Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :|
|Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :|
|Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008|
|Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017|
|Saadat, Nadia; Liu, Fangchao; Haynes, Brittany et al. (2018) Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther 17:2586-2597|
|Cheriyan, Vino T; Alsaab, Hashem; Sekhar, Sreeja et al. (2018) A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget 9:29680-29697|
|Burl, Rayanne B; Ramseyer, Vanesa D; Rondini, Elizabeth A et al. (2018) Deconstructing Adipogenesis Induced by ?3-Adrenergic Receptor Activation with Single-Cell Expression Profiling. Cell Metab 28:300-309.e4|
|Dedigama-Arachchige, Pavithra M; Acharige, Nuwan P N; Pflum, Mary Kay H (2018) Identification of PP1-Gadd34 substrates involved in the unfolded protein response using K-BIPS, a method for phosphatase substrate identification. Mol Omics 14:121-133|
Showing the most recent 10 out of 826 publications